Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice

Martijn Kuijper*, Leander Buisman, Mieke Hazes, Angelique Weel

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)965-967
Number of pages3
JournalJournal of Rheumatology
Issue number7
Publication statusPublished - Jul 2017

Cite this